ADMA Biologics (ADMA)
(Delayed Data from NSDQ)
$13.58 USD
-0.18 (-1.31%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $13.73 +0.15 (1.10%) 7:58 PM ET
1-Strong Buy of 5 1
F Value A Growth D Momentum C VGM
Brokerage Reports
ADMA Biologics Inc [ADMA]
Reports for Purchase
Showing records 21 - 40 ( 74 total )
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Fill-Finish Machine Pre-Approval Inspection Completed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Revising Revenue Outlook Based on Inventory Management; Lowering PT to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Top-Line Beat; Inventory Expansion; Supply Chain Enhancement; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Progress Remains Underappreciated; Modulating PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Knoxville Plasma Collection Center Gets FDA Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Solid Revenue Beat to Close 2020; Multiple 2021 Catalysts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Third Plasma Collection Facility Opens; Modulating PT to $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Another COVID Breakthrough but Yet Stock Below Book: Upside Not Priced-In
Provider: Jefferies & Company
Analyst: Research Department
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Top- and Bottom-Line 2Q20 Miss; Long-Term Thesis Intact; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
GC Pharma Transaction Underscores Plasma Business Value; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Newest Plasma Collection Facility Opened; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Plasma Collection From COVID-19 Recovered Patients Begins; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
2019 Financial Results Reported; Modulating Target to $12 Based on Dilution
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Tracking the Course of the Coronavirus Epidemic: KOL Conference Call Recap
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Preliminary 4Q19 Revenue Reported; 2020 Strategic Outlook; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Plasma-Derived Intermediate Fractions Monetized; Reiterate Buy; Raising Target to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
Recent Advances on Multiple Fronts; 3Q19 Financials Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: ADMA Biologics Inc
Industry: Medical - Biomedical and Genetics
First Commercial ASCENIV Sales Recorded; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R